{
    "type": "ETP",
    "ucits": false,
    "replication_method": "physical",
    "leverage": true,
    "derivatives": false,
    "swaps": false,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse Exposure",
        "Daily Rebalancing",
        "Compounding Effect"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) that seeks to provide -1x the daily performance of JPMorgan Chase & Co. equity security, tracking the iSTOXX Inverse Leveraged -1x JPM Index. It uses physical replication by holding short positions in the underlying JPMorgan Chase stock and cash balances, with no indication of synthetic replication or swap usage. The product is leveraged with a factor of -1x (inverse exposure), and explicitly warns about the compounding effect due to daily rebalancing, which can cause returns over periods longer than one day to deviate significantly from the expected inverse performance. The risk indicator is high (6 out of 7), reflecting the amplified risk from leverage and inverse exposure. The product is not UCITS compliant and is intended for sophisticated investors able to monitor positions daily. There is no capital protection, and the product may be difficult to understand due to leverage, inverse exposure, and compounding effects. No derivatives or swaps are used inherently in the strategy, but the leverage and inverse nature, combined with daily rebalancing and compounding, drive complexity under MiFID II. The PRIIPs KID and factsheet confirm physical replication and absence of swap usage. The product\u2019s complexity arises primarily from leverage, inverse exposure, and the resulting risk profile rather than derivative or swap usage."
}